Not sure why the above business article was posted.

It has to do with a manufacturing plant for Elan's drug delivery unit. Elan manufactures drugs that are developed by other companies, that use Elan's proprietary nanotechnology drug system, where they are able to reconstitute a drug by making it into nanosized particles that are more easily delivered into the body (think very small molecule) thereby using less of a drug to gain more benefit.

Tysabri scripts declined less than 1% overall, most notably during vacation time. It is thought that the PML cases did not have an effect on people who were on Tysabri and that most people who were on Tysabri chose to stay on Tysabri, with some people who were considering Tysabri either going ahead with it or choosing to wait until more investigation was done.

Elan does not manufacture Tysabri. Biogen Idec does. Although Elan invented Tysabri, their agreement with Biogen Idec provides that Biogen manufactures and controls Tysabri in the US, and Elan controls ROW, with Biogen manufacturing Tysabri for worlwide use.

As for the generation of profits, there are agreements in place where for every certain number of patients on Tysabri, Biogen must pay Elan a royalty above the normal profit share.

I could elaborate on this but this thread is for Tysabri users for information and questions about using Tysabri, not a business thread, so I will refrain.